A panelist discusses how identifying intermediate-risk patients, managing disease heterogeneity in non–muscle-invasive bladder cancer, and addressing long-term care needs present key challenges in ...

The ASPIRE trial showed SURE's noninferiority to URS in stone-free rate for nephrolithiasis treatment. SURE demonstrated superior stone clearance and residual stone volume outcomes, unaffected by ...

“I think there's a lot to be done and combination therapies, other drugs that can be instilled into this device. It's a bright future,” says Siamak Daneshmand, MD. In this video, Siamak Daneshmand, MD ...

Vibegron is the first beta-3 agonist approved for OAB symptoms in men treated for BPH, showing significant symptom improvement. The phase 3 COURAGE trial demonstrated significant reductions in ...

The series empowers surgeons to make informed family planning decisions through education, resources, and peer networking. Research indicates female surgeons face higher pregnancy complications and ...

In this interview, Michael S. Cookson, MD, MMHC, FACS, touches on the current and future applications of PSMA-PET imaging in prostate cancer. Cookson, who is a professor and the Donald D. Albers ...

“Some of the main implications for urologists is that the risk adapted utilization of BCG, which has been implemented as guidelines, should continue,” says Madison M. Wahlen. In this video, Madison M.

What are the 5 stages of bladder health? We've talked a little bit about the Man vs Prostate campaign, and it's really important that it's built upon a principle of linguistic determinism. We really ...

A panelist discusses how Non-muscle Invasive Bladder Cancer (NMIBC) treatment varies by risk stratification (low, intermediate, and high-risk), with BCG immunotherapy being standard for high-risk ...

"What's unique about our conference is the focus is not on just showcasing what our institute has to offer; the real focus is on networking and collaborating with the top institutes in the nation," ...

"The main benefit, I guess, for Aquablation over TURP, is the fact that the sexual side effects are much better when compared to TURP," says Mohamad Baker Berjaoui, MD. Let's say, first, that TURP ...

GCN2 supports prostate cancer growth by maintaining amino acid homeostasis, crucial for tumor progression. Inhibition of GCN2 alone activates p53, leading to cell cycle arrest and senescence, ...